Dana-Farber-Cancer Institute Inc.

Heska Corporation

Yuan Liu

Lan Bo Chen

Shideng Bao

Yukio Sudo

Jean-Pierre Kinet

Y-s Edmond Cheng

Marie-Helene Jouvin

John Chu

Xiuqi Qian

Disclosed are chemical agents with unexpected activity to inhibit the interactions between human immunoglobulin E (IgE) and its receptor (Fc.epsilon.RI) which interactions are known to be involved in triggering allergic responses. The agents may be used to module the allergic response in the treatment of various clinical conditions, including rhinitis, asthma, urticaria, atopic dermatitis, and anaphylacric shock. The agents can be formulated for oral, topical or parenteral administration.

Inhibition of the binding human IgE to its receptor by tetracyclic

Monoclonal antibodies to tumor marker TC1 and methods for use of same

The invention encompasses a novel tumor marker which is present on tumor cells and absent on corresponding normal cells, nucleic acid encoding the tumor marker, and a novel method of isolating DNA encoding the tumor marker or a gene which is differentially expressed in tissues.

Nucleic acids encoding tumor marker

Growing community of inventors

Lexington, MA, United States of America

Yuan Liu